| 1 |
5-fluorouracil
(11909 times)
|
Neoplasms
(5874 times)
|
CRC (610 times)
TS (558 times)
LV (492 times)
|
1963 EVALUATION OF 5-FLUOROURACIL (5-FU) IN SURGICAL PRACTICE.
|
| 2 |
5-fluorouridine
(14 times)
|
Biochemistry
(5 times)
|
DAC (3 times)
GC (3 times)
NPs (2 times)
|
1977 The ribosomes of Drosophila. Normal and defective ribosome biosynthesis in Drosophila cell cultures.
|
| 3 |
5-fluoropyrimidine
(5 times)
|
Neoplasms
(3 times)
|
PFS (3 times)
ABCG2 (1 time)
CHB-II-F (1 time)
|
2004 Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
|
| 4 |
cisplatin-5-fluorouracil
(5 times)
|
Neoplasms
(5 times)
|
SCCHN (2 times)
CI (1 time)
CR (1 time)
|
2002 Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
|
| 5 |
5-fluorouracil 5% cream
(4 times)
|
Dermatology
(3 times)
|
AK (3 times)
ALA (1 time)
CENTRAL (1 time)
|
2015 A Controlled Comparison Study of Topical Fluourouracil 5% Cream Pre-Treatment of Aminolevulinic Acid/Photodynamic Therapy for Actinic Keratosis.
|
| 6 |
5-FU group
(4 times)
|
Ophthalmology
(3 times)
|
IOP (3 times)
MMC (2 times)
POAG (2 times)
|
1989 Effect of postoperative subconjunctival 5-fluorouracil injections on the surgical outcome of trabeculectomy in the Japanese.
|
| 7 |
5-fluoro-2,4-pyrimidinedione
(3 times)
|
Pharmacology
(2 times)
|
DA (2 times)
ACh (1 time)
CNS (1 time)
|
1980 Effects on 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione(FD-1) on the central nervous system: 1. Effects on monoamines in the brain.
|
| 8 |
5-fluorouracil alone
(3 times)
|
Neoplasms
(1 time)
|
i.v (2 times)
OXA (2 times)
OXFU (2 times)
|
2000 5-fluorouracil alone versus 5-fluorouracil plus folinic acid in the treatment of colorectal carcinoma: meta-analysis.
|
| 9 |
5-fluorouracil-based
(3 times)
|
Neoplasms
(3 times)
|
MSS (1 time)
|
1996 Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
|
| 10 |
non-5-fluorouracil
(3 times)
|
Neoplasms
(2 times)
|
AE (1 time)
BTB (1 time)
CR (1 time)
|
1985 Pluripotential hematopoietic stem cells in post-5-fluorouracil murine bone marrow express the Thy-1 antigen.
|
| 11 |
((3)H)5-fluorouracil
(2 times)
|
Neoplasms
(1 time)
|
CP (1 time)
CT (1 time)
hNT1 (1 time)
|
1998 Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
|
| 12 |
5-fluorodeoxyuridine
(2 times)
|
Neoplasms
(1 time)
|
EGFR (1 time)
ODNs (1 time)
|
2002 Biological basis for chemo-radiotherapy interactions.
|
| 13 |
5-fluorouracil-induced
(2 times)
|
Antineoplastic Agents
(1 time)
|
5-FU-La (1 time)
i.p (1 time)
|
2015 Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice.
|
| 14 |
5-FU (civ)
(2 times)
|
Antineoplastic Agents
(2 times)
|
CDHP (2 times)
SRC (2 times)
|
2000 Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
|
| 15 |
5-FU + cisplatin
(2 times)
|
Neoplasms
(1 time)
|
CT (1 time)
RT (1 time)
|
1987 Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study.
|
| 16 |
5-FU resistance
(2 times)
|
Gastroenterology
(1 time)
|
MRP1 (1 time)
P-gp (1 time)
PKC (1 time)
|
2016 Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.
|
| 17 |
futraful, uracil and 5-fluorouracil
(2 times)
|
Antineoplastic Agents
(2 times)
|
BI (1 time)
BII (1 time)
FT (1 time)
|
1992 [Blood concentrations of futraful, uracil and 5-fluorouracil (5-FU) after UFT administration in the various reconstructions after gastrectomy. Saitama UFT Research Group].
|
| 18 |
(5-FU) and GEM metabolic factors
(1 time)
|
Gastroenterology
(1 time)
|
GEM (1 time)
TS (1 time)
|
2010 Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
|
| 19 |
(5-FU)-resistant Bel7402
(1 time)
|
Neoplasms
(1 time)
|
HCC (1 time)
OPN3 (1 time)
|
2012 Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
|
| 20 |
1-(2-tetrahydrofuryl)-5-fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
BBN (1 time)
DNA (1 time)
RNA (1 time)
|
2008 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil.
|
| 21 |
3-acetyl-5-fluorouracil
(1 time)
|
Pharmacology
(1 time)
|
---
|
1993 Structure of 3-acetyl-5-fluorouracil (5-FU): implication for its rearrangements during hydrolysis and upon heating.
|
| 22 |
5-(6-3H)-fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
---
|
2000 Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.
|
| 23 |
5-Fluorouracil 100mg/kg
(1 time)
|
General Surgery
(1 time)
|
PH (1 time)
SOS (1 time)
|
2015 Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer.
|
| 24 |
5-fluorouracil 400 mg/m2 per day
(1 time)
|
Neoplasms
(1 time)
|
---
|
1991 Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin.
|
| 25 |
5-fluorouracil needling
(1 time)
|
Ophthalmology
(1 time)
|
MMC (1 time)
NPDS (1 time)
|
2011 Resources use, costs and effectiveness of non-penetrating deep sclerectomy according to glaucoma stage.
|
| 26 |
5-fluorouracil treatment
(1 time)
|
Genetics
(1 time)
|
SpD (1 time)
|
2015 A Diet Containing Beta-Hydroxy-Beta-Methylbutyrate, L-Glutamine and L-Arginine Ameliorates Chemoradiation-Induced Gastrointestinal Injury in Rats.
|
| 27 |
5-fluorouracil, consists of tegafur
(1 time)
|
Antineoplastic Agents
(1 time)
|
---
|
2001 [A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
|
| 28 |
5-fluorouracil-1-yl-aceto amino acid, 5-FUAA
(1 time)
|
Allergy and Immunology
(1 time)
|
5-FUAA-BSA (1 time)
5-FUAA-OVA (1 time)
BSA (1 time)
|
2016 [Preparation and characterization of polyclonal antibody against 5-fluorouracil].
|
| 29 |
5-fluorouracil-resistant
(1 time)
|
Neoplasms
(1 time)
|
CRC (1 time)
EMT (1 time)
|
2017 Rufy3 promotes metastasis through epithelial-mesenchymal transition in colorectal cancer.
|
| 30 |
5-fluorouridine-containing
(1 time)
|
Biochemistry
(1 time)
|
MN (1 time)
Psi (1 time)
snRNA (1 time)
|
1997 Modification of human U4 RNA requires U6 RNA and multiple pseudouridine synthases.
|
| 31 |
5-fluoruracil/capecitabine
(1 time)
|
Neoplasms
(1 time)
|
AEs (1 time)
PA (1 time)
SCC (1 time)
|
2018 Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes.
|
| 32 |
5-fluourouracil-loaded polyactic acid nanoparticles PLA
(1 time)
|
Ophthalmology
(1 time)
|
---
|
2006 [Experimental study on 5-fluourouracil-loaded immunonanoparticles targeting to lens epithelial cells].
|
| 33 |
5-FU arm
(1 time)
|
Antineoplastic Agents
(1 time)
|
NDP (1 time)
PS (1 time)
|
2007 [Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
|
| 34 |
5-FU by CVI
(1 time)
|
Antineoplastic Agents
(1 time)
|
CVI (1 time)
|
1999 [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
|
| 35 |
5-FU from drug
(1 time)
|
Biology
(1 time)
|
beta-CD (1 time)
EE (1 time)
FTIR (1 time)
|
2016 Formation and characterization of beta-cyclodextrin (beta-CD) - polyethyleneglycol (PEG) - polyethyleneimine (PEI) coated Fe3O4 nanoparticles for loading and releasing 5-Fluorouracil drug.
|
| 36 |
5-FU persistent arterial method
(1 time)
|
Antineoplastic Agents
(1 time)
|
FAM (1 time)
IP (1 time)
|
1994 [A study of various complications in arterial infusion chemotherapy].
|
| 37 |
5-FU resistant cell line H630
(1 time)
|
Neoplasms
(1 time)
|
CRC (1 time)
DS (1 time)
|
2003 Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines.
|
| 38 |
5-FU, 600 mg/m2 intravenously weekly
(1 time)
|
Neoplasms
(1 time)
|
LDH (1 time)
|
1986 Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
|
| 39 |
5-FU-HAGS
(1 time)
|
Nanotechnology
(1 time)
|
PLGA (1 time)
|
2013 Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors.
|
| 40 |
5-FU-resistant cell line
(1 time)
|
Complementary Therapies
(1 time)
|
CCK-8 (1 time)
FCM (1 time)
HSP-27 (1 time)
|
2019 Curcumin Reverses 5-Fluorouracil Resistance by Promoting Human Colon Cancer HCT-8/5-FU Cell Apoptosis and Down-regulating Heat Shock Protein 27 and P-Glycoprotein.
|
| 41 |
5-FUci
(1 time)
|
Neoplasms
(1 time)
|
VEGF (1 time)
|
2007 Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
|
| 42 |
5-FUra
(1 time)
|
Antineoplastic Agents
(1 time)
|
HU (1 time)
|
1985 Factors modifying cytotoxicity induced by 5-FU and hydroxyurea.
|
| 43 |
5FU-AEs
(1 time)
|
Genetics, Medical
(1 time)
|
AEs (1 time)
|
2016 Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
|
| 44 |
agent5-fluoruracil
(1 time)
|
|
---
|
2019 Bioelectrical Analysis of Various Cancer Cell Types Immobilized in 3D Matrix and Cultured in 3D-Printed Well.
|
| 45 |
bevacizumab-5-fluorouracil
(1 time)
|
Gastroenterology
(1 time)
|
LARC (1 time)
TME (1 time)
|
2019 Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
|
| 46 |
docetaxel-5-fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
ORR (1 time)
SCCHN (1 time)
|
2004 Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
|
| 47 |
drugs-5-fluorouracil
(1 time)
|
Environmental Health
(1 time)
|
cisPt (1 time)
ET (1 time)
hpf (1 time)
|
2016 Acute and sub-chronic toxicity of four cytostatic drugs in zebrafish.
|
| 48 |
Facilitated uptake of 5-fluorouracil
(1 time)
|
Nanotechnology
(1 time)
|
---
|
2016 Transmembrane delivery of anticancer drugs through self-assembly of cyclic peptide nanotubes.
|
| 49 |
failure undergoing trabeculectomy with 5-Fluorouracil
(1 time)
|
Ophthalmology
(1 time)
|
IOP (1 time)
|
1993 Intra-operative use of 5-fluorouracil in glaucoma filtering surgery.
|
| 50 |
first-line chemotherapy combination with lrinotecan+5-Fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
ACC (1 time)
OS (1 time)
PD (1 time)
|
2002 Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
|
| 51 |
first-line treatment was cisplatin+5-fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
HCRU (1 time)
PS (1 time)
SCCHN (1 time)
|
2018 Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom.
|
| 52 |
Fluoro Uracil
(1 time)
|
Cell Biology
(1 time)
|
bFGF (1 time)
DPD (1 time)
TPP (1 time)
|
2009 Enhanced cytotoxicity of 5-FU by bFGF through up-regulation of uridine phosphorylase 1.
|
| 53 |
Fluoro-uracile, Roche, France
(1 time)
|
Antineoplastic Agents
(1 time)
|
HPLC (1 time)
|
1992 Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
|
| 54 |
Fluoroblastin, Farmitalia, Freiburg, Germany
(1 time)
|
Gastroenterology
(1 time)
|
CAI (2 times)
|
1997 Celiac artery adjuvant chemotherapy. Results of a prospective trial.
|
| 55 |
Fluoropyrimidines-5-fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
---
|
2016 Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
|
| 56 |
fluorouracil-resistant SNU-C5
(1 time)
|
Pharmacology
(1 time)
|
---
|
2016 The Effect of (1S,2S,3E,7E,11E)-3,7,11,15-Cembratetraen-17,2-Olide (LS-1) from Lobophyyum sp. on the Apoptosis Induction of SNU-C5 Human Colorectal Cancer Cells.
|
| 57 |
follows: untreated control; 5-fluorouracil
(1 time)
|
Biochemistry
(1 time)
|
o-rMETase (1 time)
OXA (1 time)
PDOX (1 time)
|
2019 Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model.
|
| 58 |
frequently used chemotherapeutic drug 5-fluorouracil
(1 time)
|
Cardiology
(1 time)
|
---
|
2005 Coronary artery spasm induced by 5-fluorouracil.
|
| 59 |
frequently used drugs: 5-fluorouracil
(1 time)
|
Drug Therapy
(1 time)
|
FUdR (1 time)
|
1998 Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.
|
| 60 |
FU-ALA-PDT
(1 time)
|
Diagnostic Imaging
(1 time)
|
ALA-PDT (1 time)
|
2016 Enhancing the efficiency of 5-aminolevulinic acid-mediated photodynamic therapy using 5-fluorouracil on human melanoma cells.
|
| 61 |
FU-PLA-mc
(1 time)
|
General Surgery
(1 time)
|
---
|
1986 [A new anticancer preparation, 5-fluorouracil-poly-L-lactic acid microcapsule, and its therapeutic evaluation].
|
| 62 |
gemcitabine-5-fluorouracil
(1 time)
|
Neoplasms
(1 time)
|
AIO (1 time)
|
2007 Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
|
| 63 |
parthenolide-5-fluorouracil
(1 time)
|
Chemistry
(1 time)
|
---
|
2019 Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
|
A Search Service for Abbreviation / Long Form